0
Clinical Investigations: ASTHMA |

The Effectiveness of IV β-Agonists in Treating Patients With Acute Asthma in the Emergency Department*: A Meta-analysis

Andrew H. Travers, MD, MSc; Brian H. Rowe, MD, MSc; Samantha Barker, MD; Arthur Jones, RT; Carlos A. Camargo, Jr, MD, DrPH
Author and Funding Information

*From the Division of Emergency Medicine (Drs. Travers and Rowe) and Department of Radiology (Dr. Barker), University of Alberta and Capital Health Authority, Edmonton, AB, Canada; Respiratory Care Department (Mr. Jones), University of Texas, San Antonio, TX; and the Department of Emergency Medicine (Dr. Camargo), Massachusetts General Hospital Boston, MA.

Correspondence to: Andrew Travers, MD, MSc, Division of Emergency Medicine, University of Alberta, 1G1.50 WMC, 8440-112th St, Edmonton, AB, T6G 2B7 Canada; e-mail: ahtravers@shaw.ca



Chest. 2002;122(4):1200-1207. doi:10.1378/chest.122.4.1200
Text Size: A A A
Published online

Objectives: To determine the benefit of IV β2-agonists for severe acute asthma treated in the emergency department (ED).

Methods: Randomized controlled trials were identified using EMBASE, MEDLINE, and CINAHL; the Cochrane Airways Review Group database; hand searching; bibliographies; pharmaceutical companies; and author contact. Studies where IV β2-agonists were compared to placebo and/or existing standards of care were considered. Where appropriate, trials were combined using odds ratios (ORs) or weighted mean differences with 95% confidence intervals (CIs).

Results: From 746 identified references, 55 potentially relevant articles were identified and 15 articles were included. All trials were performed outside North America and were published prior to 1997. Three main treatment strategies were reviewed: strategy 1 (three articles), IV β2-agonists with inhaled β2-agonists vs inhaled β2-agonists; strategy 2 (six articles), IV β2-agonists alone vs inhaled β2-agonists; and strategy 3 (six articles), IV β2-agonists vs IV methylxanthines. Compared to all treatments, IV β2-agonist use did not lead to clinical or statistical significant differences in vital signs, pulmonary functions, laboratory measures, adverse effects, or clinical success. Although statistically nonsignificant, seven methodologically strong studies demonstrated that peak expiratory flows and heart rates were unchanged following β2-agonist use compared to all other treatments at 60 min (8.3 L/min [95% CI, 17.6 to 34.2] and 3.65 beats/min [95% CI, 2.9 to 10.2], respectively), with an increased risk of adverse effects (OR, 1.98; 95% CI, 0.5 to 8.2).

Conclusions: Evidence is lacking to support the use of IV β2-agonists in ED patients with severe acute asthma. Moreover, the clinical benefit appears questionable, while the potential clinical risks are obvious. The only recommendations for IV β-2agonist use should be in those patients in whom inhaled therapy is not feasible, or in the context of a controlled clinical trial comparing IV β2-agonists with standard care vs standard care alone.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543